Sign In
Buy VKTX
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights
06:51pm, Friday, 19'th Apr 2024
Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $63.42, signifying a -1.93% move from its prior day's close.
Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.
07:09pm, Tuesday, 16'th Apr 2024
A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
01:19pm, Tuesday, 16'th Apr 2024
Investors looking for a white-knuckle ride can easily find one by buying biotech stocks. There is a certain thrill in investing in a company making actual life-or-death decisions with drugs.
3 Magnificent Stocks That Could Double or More by 2030
08:47am, Saturday, 13'th Apr 2024
CRISPR Therapeutics has significant upside potential. Eli Lilly could become an even bigger healthcare giant.
Shed the Fat, Gain the Profits: 3 Weight-Loss Stocks to Own Until 2027
06:25am, Friday, 12'th Apr 2024
Weight-loss stocks remain the focus of many investors. The GLP-1 drugs that many companies have put forward address key health concerns like obesity and diabetes, which have become epidemics in many W
If You Can Only Buy One Biotech Stock in April, It Better Be One of These 3 Names
01:49pm, Thursday, 11'th Apr 2024
Biotech stocks are one of the hottest investing opportunities in the stock marketlately. The optimism surrounding the industry is evident in the SPDR S&PBiotech ETF's (NYSEARCA: XBI ) 25% bump in valu
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
09:27am, Wednesday, 10'th Apr 2024
A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.
06:45am, Tuesday, 09'th Apr 2024
Weight loss medications are fueling the pharmaceutical industry right now. One potential side effect of losing weight can be reductions in muscle mass -- which can pose serious health issues.
Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It.
05:55am, Monday, 08'th Apr 2024
Viking aims to challenge big pharma players Eli Lilly and Novo Nordisk in the multibillion-dollar weight loss drug market. It recently reported excellent clinical trial results for its injectable and
Is it Too Late to Buy Viking Therapeutics Stock?
07:45am, Saturday, 06'th Apr 2024
Upstart biotech Viking Therapeutics is hoping to enter the weight loss treatment market. The company has released encouraging data from clinical trials for its candidate, VK2735.
Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics
07:15am, Friday, 05'th Apr 2024
Madrigal Pharmaceuticals just commercialized its first medicine. Viking Therapeutics has a mid-stage candidate with great potential.
Viking Therapeutics Just Announced More Positive Results: Time to Buy?
09:15am, Thursday, 04'th Apr 2024
Viking Therapeutics is testing an oral version of its leading candidate. The biotech recently reported positive phase 1 results for this formulation.
1 Brand-New (Good) Reason to Buy Viking Therapeutics Stock Now
06:30am, Thursday, 04'th Apr 2024
There's an ongoing gold rush for medicines that treat obesity. Viking Therapeutics already has two strong contenders in clinical trials.
Could This 1 Detail Help Viking Therapeutics Top Eli Lilly and Novo Nordisk in the Weight Loss Drug Market?
04:55am, Thursday, 04'th Apr 2024
Eli Lilly and Novo Nordisk have seen demand surpass supply of their weight loss drugs. Their revenues have soared thanks to these popular products.
Viking Therapeutics Surges Sentiment for Triple Threat GLP-1Pill
06:20am, Wednesday, 03'rd Apr 2024
GLP-1 (Semaglutide) drugs like Ozempic and Wegovy produced by Novo Nordisk A/S NYSE: NVO and Mounjaro and Zepbound (Tirzepatide) produced by Eli Lilly and Co. NYSE: LLY have taken the mainstream by st
